M

Madrigal Pharmaceuticals

Biopharmaceutical firm developing NASH therapies

Overview

Madrigal Pharmaceuticals develops therapies for nonalcoholic steatohepatitis (NASH) and related liver diseases, focusing on patients with moderate to advanced fibrosis and compensated cirrhosis. Its first therapy has FDA accelerated approval and is in Phase 3 trials, with revenue from sales and potential partnerships. The exact mechanism of action isn’t detailed, but the product has demonstrated clinical benefit in trials and ongoing safety validation. The company differentiates itself by a focused NASH program with accelerated approval and continued Phase 3 development, plus possible licensing deals, aiming to bring approved treatments to patients.

Work here?Claim your company

About Madrigal Pharmaceuticals

Simplify's Rating
Why Madrigal Pharmaceuticals is rated
B
Rated B on Competitive Edge
Rated A on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

West Conshohocken, PA

Founded

2011

Get referred to Madrigal Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Third-quarter 2026 Rezdiffra sales hit $431.3 million, with first-quarter profitability achieved.
  • Patient count topped 55,850 by September 30, 2026, showing accelerating prescriber adoption.
  • MAESTRO-CSPH starts in first half 2027, creating a new catalyst for cirrhosis expansion.

What critics are saying

  • Rezdiffra depends on one product; any safety signal would crush Madrigal immediately.
  • European uptake stays weak in 2026 because MFN pricing blocks reimbursement.
  • Novo Nordisk, Lilly, and Inventiva are advancing MASH drugs that can displace Rezdiffra by 2028.

What makes Madrigal Pharmaceuticals unique

  • Rezdiffra is the first FDA and EU-approved MASH therapy for F2-F3 fibrosis.
  • Madrigal owns a deep MASH development stack: F4c outcomes, MAESTRO-CSPH, and siRNA programs.
  • U.S. patent coverage for Rezdiffra now stretches into 2045 on key dosing claims.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$2.3B

Above

Industry Average

Funded Over

11 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Company Match
  • Company Equity
  • Hybrid Work Options
  • Mental Health Support

Recently Posted Jobs

Sign up to get curated job recommendations

Madrigal Pharmaceuticals is Hiring for 60 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs